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Purpose: To evaluate the prevalence, factors, and clinical impact of self-expanding stent fracture following iliac artery
stenting.
Materials and Methods: A review of the endovascular registry database for our department showed 353 patients with
occlusive diseases of the iliac artery who underwent stenting between 1997 and 2007. While clinical data and images were
retrospectively reviewed for all patients, 165 patients who underwent self-expanding stenting and plain radiograph with
>6-months follow-up were analyzed. Mean follow-up was 43 months for 305 stents (elgiloy, n  83; nitinol, n  222)
implanted in 216 iliac arteries. The mean duration until the last imaging study was 38 months. Items concerning
prevalence of stent fracture, factors associated with fracture, and outcomes for patients with stent fracture were analyzed.
Results: Stent fracture was detected in 11 of 216 iliac arteries (5.1%). In stent-based analysis, 11 of 305 stents (3.6%)
showed stent fracture, classified as type I in 2 stents, type II in 3 stents, type III in 4 stents, type IV in 1 stent, and type
V in 1 stent. Stent fracture was detected in 11 of 222 nitinol stents (5.0%), but no Elgiloy stents. Cox proportional
hazards regression model indicated stenting for chronic occlusion as a risk factor associated with nitinol stent fracture
(hazard ratio [HR]  6.09, P  0.008, 95% confidence interval [CI] 1.59-23.3). Cumulative primary patency rates in
iliac arteries with and without fractured stents were 90% and 91% at 8 years (P  .80), respectively.
Conclusion: Fracture of self-expanding stents is rare in iliac arteries, but stenting for chronic occlusion represents a risk
factor for fracture. Fractures of stents placed in iliac arteries rarely affect patency. (J Vasc Surg 2009;49:645-52.)Endovascular treatment is more established for iliac
artery occlusive disease than for infrainguinal lesions.1,2
Stent fracture remains an issue of major concern leading to
in-stent restenosis in femoropopliteal disease, as the femo-
ropopliteal artery displays unique anatomical and func-
tional features, such as torsion, compression, flexion, and
extension.3-6 Iliac artery conformation, particularly exter-
nal iliac artery (EIA), is changed by bending of the hip
joint, so stents placed in iliac arteries could be mechanically
stressed.7 A case of stent reocclusion with a fractured self-
expanding stent in the common iliac artery (CIA) has been
already reported.8 However, few studies have focused on
self-expanding stent fracture following iliac artery stenting,
despite the wide use of stent placement in the iliac arteries.
The purpose of this study was to evaluate the preva-
lence, factors, and clinical impacts of self-expanding stent
fracture following iliac artery stenting.
MATERIALS AND METHODS
Study design. According to a review of the endovas-
cular registry database for our department, 353 consecutive
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doi:10.1016/j.jvs.2008.10.019patients with iliac artery occlusive disease underwent stent-
ing between 1997 and 2007. During this period, all of our
patients underwent primary stenting without predilatation
or with predilatation using a small-diameter balloon, and
with postdilatation using an adequate-diameter balloon,
selected based on the reference diameter if necessary. In this
study, clinical data and images were retrospectively re-
viewed for all patients, and patients who underwent self-
expanding stenting and plain radiograph with 6-months
follow-up were analyzed. According to our strategy, we
placed a balloon-expandable stent at lesions showing heavy
calcification and/or a short segment, particularly in the
CIA. We usually use a self-expanding stent at other lesions.
According to our database, 292 of the 353 patients
were treated using self-expanding stents. Of 292 patients
who underwent self-expanding stent placement, 127 pa-
tients did not undergo plain radiography or achieve 6
months of follow-up. One hundred one of 292 patients
treated with self-expanding stents (35%) were lost to
follow-up. Thus, a total of 165 patients were analyzed in
this study. Mean duration of follow-up was 43  26
months. The mean duration until the last imaging study
was 38 months.
A total of 305 stents (elgiloy, n 83; nitinol, n 222)
were implanted in 216 iliac arteries, including 69 occlu-
sions (32%). According to Trans Atlantic Inter-Societal
Consensus (TASC) classification, 39 (24%) patients were
classified type A, 65 (39%) in type B, 37 (22%) in type C,
and 24 (15%) in type D. In principle, the type of stent was
selected according to the preferences of the physician.
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were the only commercially-available self-expanding stents
in our country in the 1990s. Luminexx (Bard, Murray Hill,
NJ) stents subsequently became available since 2004, and
SMART (Cordis, Miami Lakes, Fla) stents have been avail-
able since 2005. We have enrolled patients for various
feasible and pivotal trials of several types of self-expanding
stents. Thus, stent selection depended on trial enrollment,
the commercially-available inventory at the time, and the
preferences of the physician. All Elgiloy stents implanted
were Wallstents. Nitinol stents implanted included 103
Luminexx stents, 44 SMART stents, 32 SelfX stents (Ab-
bott Medical Devices), 24 Memotherm stents (Bard), 13
Zilver stents (CookMedical, Bloomington, Ind), and 6 ZA
stents (CookMedical). Overlap stenting underwent with at
least 10mmoverlap length.Mean stented length was 9.7
4.0 cm. Patient characteristics are summarized in Table I.
This retrospective review did not require institutional
review board approval according to our institutional guide-
lines.
Follow-up protocol. Our general follow-up program
for patients with iliac artery stenting included clarification
of symptoms, clinical examination, and ankle brachial index
Table I. Summary of patient characteristics
Total
No. patients 165
Age (years) 71  8.1
Male 150 (91%)
No. iliac arteries 216
Follow-up (months) 43  26
Rutherford classification
Category
1 7 (4%)
2 75 (45%)
3 74 (45%)
4 6 (4%)
5 3 (2%)
TASC
Type
A 39 (24%)
B 65 (39%)
C 37 (22%)
D 24 (15%)
Lesion length (cm) 7.1  4.3
Lesion site
CIA 52 (24%)
EIA 92 (43%)
CIA-EIA 72 (33%)
Lesion type
Stenosis 147 (68%)
Occlusion 69 (32%)
Stent length (cm) 7.2  2.2
Number of stents (%)
Numbers 305
Single 135 (62%)
Multiple 81 (38%)
Stented length (cm) 9.7  4.0
P value* indicates P values between nitinol and Elgiloy stents.
†4 patients were double-counted.(ABI) pre-discharge and at 30 days, 3 months, and everysubsequent 3 months after stent implantation. Duplex
sonography scan was performed pre-discharge and at 6
months, 1 year, and each subsequent year after stenting.
Biplanar plain radiograph (anterior-posterior and lateral
projections) with hip joint extended and hip joint bent at
90° for evaluation of structural integrity of the stent was
generally performed pre-discharge and at 6 months, 1 year,
and bi-annually after stent implantation. Radiography was
performed using computed radiography and flat-panel ra-
diography. Stent fracture was evaluated by radiography or
using a Picture Archiving and Communication System
viewer (SYNAPSE, Fujifilm Medical, Tokyo, Japan).
Clinical patency was evaluated according to symptoms
and resting ABI. If resting ABI was decreased 0.15 com-
pared with baseline, the patient underwent an ultrasonog-
raphy scan to detect in-stent restenosis or de novo lesion.
Patients were followed for in-stent restenosis 50% with
duplex sonography scan, CT angiography, or angiography
to determine the best method of management.
Parameters investigated. The following parameters
were investigated: (1) prevalence of stent fracture; (2)
factors associated with fracture; and (3) outcomes for pa-
tients with stent fracture. Stent fracture was classified ac-
Nitinol Elgiloy P value*
122
†
47
†
71  7.6 70  9.1 0.45
110 (90%) 44 (94%) 0.69
156 60
32  25 50  22 0.001
5 (4%) 2 (4%) 0.91
53 (43%) 22 (47%)
58 (48%) 20 (43%)
3 (2.5%) 3 (6%)
3 (2.5%) 0 (0%)
30 (25%) 11 (23%) 0.15
48 (39%) 17 (36%)
31 (25%) 7 (15%)
13 (11%) 12 (26%)
6.9  4.0 7.3  4.7 0.56
38 (24%) 15 (25%) 0.80
64 (41%) 27 (45%)
54 (35%) 18 (30%)
108 (69%) 39 (65%) 0.66
48 (31%) 21 (35%)
7.1  2.2 7.4  2.2 0.37
222 83
96 (62%) 39 (65%) 0.75
60 (38%) 21 (35%)
9.6  3.9 9.8  4.2 0.75cording to standardized evaluation and reporting of stent
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by Jaff et al9 Rocha-Singh et al10 (classification of stent
fracture, type I; single tine fracture, type II; multiple tine
fractures, type III; stent fracture with preserved align-
ment of the components, type IV; stent fracture with
mal-alignment of components, type V; stent fracture in a
trans-axial spiral configuration). The prevalence of stent
fracture was calculated on a per stent basis, and also on a per
iliac artery basis. Factors that may be predictive of stent
fracture were evaluated by uni- and multivariate analysis.
These factors included symptom (intermittent claudication
vs critical limb ischemia), stented length, portion of occlu-
sive artery (CIA, EIA, or CIA-EIA), lesion type (occlusion
vs stenosis), and number of stents (single use vs multiple
use).
Statistical analysis. Continuous data are shown as
mean standard deviation.Discrete data are shown as counts
and percentages. The 2 tests and unpaired t tests were used
for comparison between two groups. Risk factors for stent
fracture were evaluated by univariate and multivariate anal-
ysis using Cox proportional hazards regression. Cumulative
primary patency rate was estimated using Kaplan-Meier
methods with the log-rank test. Findings were considered
significant if the resulting P value was less than .05. All
statistical tests were performed using SPSS for Windows
version 11.0J software (SPSS, Chicago, Ill).
RESULTS
Stent fracture was detected in 11 of 216 iliac arteries
(5.1%). In stent-based analysis, 11 of 305 stents (3.6%)
showed stent fractures, classified as type I in 2 stents, type II
in 3 stents, type III in 4 stents, type IV in 1 stent, and type
V in 1 stent. Stent fracture was detected in 11 of 222 nitinol
stents (5.0%), but none in Elgiloy stents. Analyzing the
performance of different stents revealed a 4.9% fracture rate
(5 of 103) for Luminexx stents, 4.5% (2 of 44) for SMART
stents, 6.3% (2 of 32) for SelfX stents, 8.3% (2 of 24) for
Memotherm stents, 0% (0 of 13) for Zilver stents, and 0%
(0 of 6) for ZA stents. No significant difference in fracture
rates was seen among different types of stent. Furthermore,
no significant differences in fracture rate were seen among
the three most frequently used types of stent (Wallstent,
Luminexx stent, and SMART stent). Fractured stents were
detected in four iliac arteries treated using a single stent;
while it was seen in seven iliac arteries treated usingmultiple
numbers of stents. Stent fracture was observed at the distal
end of overlap site in five of seven iliac arteries treated using
multiple stenting. Two stent fractures were observed at
CIA, whereas nine stent fractures were seen at EIA.
Only the nitinol stent group was analyzed for factors
associated with stent fracture and patency rates, because
stent fracture was not seen in the Elgiloy group. In this
study, 2 patients underwent multiple stenting using a com-
bination of two different stents. These patients were di-
vided into two groups according to the longer length of
each stent. There was statistically significant difference in
lesion type (stenosis or occlusion) between the fracture andno fracture group treated using nitinol stent (P  .005)
(Table II). Univariate analysis using Cox proportional haz-
ards regression model indicated that stenting for occlusion
should be considered as a risk factor for nitinol stent
fracture (P  .02). A relative tendency was seen for lesions
affecting both the CIA and EIA to be associated with
fracture on univariate analysis (P  .07). No other signifi-
cant differences were seen on univariate analysis (Table III).
Therefore, lesion site and lesion type were evaluated by
multivariate analysis for determining a factor associated
with nitinol stent fracture.
Multivariate analysis using Cox proportional hazards
regression model (Table III) indicated stenting for chronic
occlusion as a risk factor associated with stent fracture
(hazard ratio [HR]; 6.09, P .008, 95% confidence inter-
val [CI] 1.59 to 23.3). The HR for stenting in CIA-EIA
disease was 4.81 (95% CI 0.99-23.4), and a relative ten-
dency toward stent fracture was seen (P  .052).
Reocclusion of iliac artery stented was detected in 1 of
11 iliac arteries with stent fracture. This patient underwent
recanalization by stent-in-stent maneuver. Cumulative
primary patency rates in iliac arteries with and without
fractured stents were 90% and 93% at 3 years, 90% and 91%
at 5 years, and 90% and 91% at 8 years, respectively.
Cumulative-assisted primary patency rates in iliac arteries
with and without fractured stents were 90% and 97% at 3
years, 90% and 97% at 5 years, and 90% and 97% at 8 years,
respectively. No significant difference in cumulative pri-
mary patency rate and assisted primary patency rate (P 
.80 and P  .20) was seen between groups (Figs 1 and 2).
Reocclusion which was not able to be recanalized by endo-
vascular procedure was detected in a single iliac artery
stented without fracture, but it was not detected with stent
fracture. Cumulative secondary patency rates with and
Table II. Differences in factors between fracture and no
fracture group treated with nitinol stent
Factors Fracture No fracture P value
Number 11 145
Age (year) 71  8.5 72  8.4 .71
Symptom
IC 10 139 .99
CLI 1 6
Lesion site (%)
CIA 2 (18%) 36 (25%) .22
EIA 2 (18%) 62 (43%)
CIA-EIA 7 (64%) 47 (32%)
Lesion type (%)
Stenosis 3 (27%) 105 (72%) .005
Occlusion 8 (73%) 40 (28%)
Stented length (cm) 11.3  5.0 9.5  3.8 .27
Number of stents (%)
Single 4 (36%) 92 (63%) .12
Multiple 7 (64%) 53 (37%)
IC, Intermittent claudication; CLI, critical limb ischemia; CIA, common
iliac artery;EIA, external iliac artery;CIA-EIA, common iliac artery-external
iliac artery.without fractured stents were 100% and 100% at 3 years,
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respectively. Aneurysmal dilatation was detected in the one
iliac artery with type IV fracture (Fig 3) and the one iliac
artery with type V fracture.
DISCUSSION
Balloon-expandable stents are subject to extrinsic com-
pression and deformation, and stent fracture and restenosis
of first-generation balloon-expandable stents placed in the
EIA was reported several years ago.11 Self-expanding stents
have been considered to provide a satisfactory alternative by
reversion to normal configuration with shape memory, and
a large number of self-expanding stents have now been
implanted for peripheral arterial occlusive disease. With
increasing numbers of cases treated using endovascular
therapy, the disadvantages that can accompany endovascular
treatment using self-expanding stents for peripheral arterial
occlusive disease are now being clarified. Most disadvantages
associated with endovascular therapy using self-expanding
stents involve in-stent restenosis and stent fracture following
femoropopliteal artery stenting.4,5,12 Self-expanding stent
fractures in peripheral vessels have been described in several
other fields, such as the carotid13,14 and subclavian arter-
ies.15 Prevalence and adverse events associated with self-
expanding stents, however, are not well-known for the iliac
artery, although we have already reported a single case of
self-expanding stent fracture in the CIA.8
The present study indicated a 5.1% prevalence of stent
fracture in 216 iliac arteries and 3.6% in 305 stents follow-
ing iliac artery stenting. Fracture rates in femoropopliteal
arteries have previously been reported at 2-53%4,5,16 The
prevalence of stent fracture following iliac artery stenting
is lower compared to the femoropopliteal artery according
to several reports using similar types of stents to our
study.4,5,12,17 However, this result may suggest that we
should consider stent fracture following iliac artery stent-
ing. The rate of fracture might depend on stent design and
stented length according to previous studies of femoropop-
liteal stenting.4,12,16-20 Based on anatomical features, sev-
Table III. Risk factors for fracture of nitinol stent analyze
Univariat
Study variable/referent
variable HR [95% CI]
Lesion site
CIA/EIA 1.67 [0.23-11.9]
CIA-EIA/EIA 4.28 [0.89-20.6]
Lesion type
(Ocel/Stens) 5.07 [1.34-19.3]
Stented length (per 1 cm) 1.11 [0.96-1.28]
Number of stents
Multi/Single 2.46 [0.72-8.42]
Symptom
IC/CLI 0.28 [0.03-2.22]
HR, Hazard ratio; 95% CI, 95% confidential interval; CIA, common iliac a
claudication; CLI, critical limb ischemia.eral differences exist between the iliac and femoropoplitealarteries. Although the femoropopliteal artery runs through
muscles, the iliac artery is surrounded only by retroperito-
neal fat. This feature could be associated with differences in
the rate of stent fracture between the iliac artery and
femoropopliteal arteries. Second, lesion length was shorter
in the present study compared with previous investigations
concerning femoropopliteal artery stenting. In addition,
the number of overlap sites might be small in iliac arteries
compared with femoropopliteal arteries.
Several mechanisms must be considered for stent frac-
ture in the iliac artery. We have previously reported that the
iliac artery, particularly EIA, is exposed to flexion by bend-
ing the hip joint,7 which seems likely to be associated with
stent fracture in iliac arteries. In this study, stent fracture
was detected in CIA as well as EIA. Fracture of stent placed
in CIA might be affected by the complex motion intro-
duced by the spine in addition to the hip movements.
Another cause of stent fracture may be internal stress on the
structure. A significant amount of internal stress is consid-
ered to be transmitted to the stent material as a result of
pulsatile flow. This phenomenon is described as higher in
stents placed in the pulmonary artery or aorta.21,22 How-
ever, whether the iliac artery can be affected by pulsatile
blood flow as in great vessels has not been established.
Previous studies of the femoropopliteal artery have
indicated that fracture rate is significantly lower for short-
stented segments than for longer-stented segments,4,5,19,20
and Scheinert et al4 demonstrated that fracture rate is also
significantly lower for single stents than for 3 stents. In
the present study, stented length, lesion site, or number of
stents implanted were not associated with stent fracture.
The present study results indicate that placement in an
occluded artery is a risk factor for stent fracture. A guide-
wire often gains partial entry into the subintimal space
during recanalization of occluded arteries. Logically, stents
may be placed into the subintimal space following recana-
lization with a guidewire through the subintimal space. A
stent placed in the subintimal space may be eccentrically
ng Cox proportional hazards regression model
Multivariate
P value HR [95% CI] P value
.61 1.29 [0.18-9.25] .80
.07 4.81 [0.99-23.4] .052
.02 6.09 [1.59-23.3] .008
.14 not evaluated
.15 not evaluated
.23 not evaluated
EIA, external iliac artery; Stens, stenosis; Occl, occlusion; IC, intermittentd usi
e
rtery;compressed by plaque and thrombus present in the true
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and thrombus might be transformed into an ellipse when
considering the image perpendicular to the longitudinal
direction of the stent. This form seems likely to display
different rigidity between directions along the major and
minor axes. Extrinsic or intrinsic forces might thus place
pressure on the stent with fixed directions. As a result, stent
fracture could be detected significantly more frequently in
occluded arteries compared with stenotic arteries.
Fracture rates of self-expanding stents have indicated a
wide variability of 2-53% for some stent designs.4,5,16 El-
giloy stents display unique features compared with nitinol
Fig 1. Cumulative primary and assisted primary patency rates.
a, Cumulative primary patency rates in iliac arteries with and
without fractured stent were 90% and 93% at 3 years, 90% and
91% at 5 years, and 90% and 91% at 8 years, respectively. b,
Cumulative assisted primary patency rates in iliac arteries with
and without fractured stent were 90% and 97% at 3 years, 90%
and 97% at 5 years, and 90% and 97% at 8 years, respectively. No
significant difference in cumulative primary patency rate and
assisted primary patency rate (P  .80 and P  .20) was seen
between groups.stents. The Wallstent (an Elgiloy stent) is made from bio-medical super alloy wire with a radiopaque core braided in
a tubular mesh configuration, whereas nitinol stents use a
basic zigzag pattern with open- or closed-cells. No fracture
of Elgiloy stents was observed in the present study. The
fracture rate could be relatively lower for Wallstent than for
SMART stents in femoropopliteal arteries.5 Few specula-
tions have been reported concerning the variability of frac-
ture rates between Elgiloy and nitinol stents. Wallstent
shows foreshortening, which is disadvantageous for endo-
vascular procedures. Peripheral arteries are affected by lon-
gitudinal compression, with arterial length shortening up
to 13% in the femoropopliteal artery.3 The tubular mesh
configuration for Wallstent, which results in foreshorten-
ing, might produce advantages in longitudinal change of
arterial length. A tubular mesh with longitudinal spiral wire
may result in the stent cross-section showing oval deforma-
tion rather than ellipse around the area compressed by
plaque. Different types of nitinol stent show variable zigzag
and spiral designs, and methods of polishment. Stent de-
sign could affect axial strength and longitudinal flexibility.
Material fatigue may also depend on the surface treatment.
Electropolished instruments performed significantly better
than nonelectropolished instruments in fatigue testing.23
The benefits of electropolishing are likely to be caused by a
reduction in surface irregularities that serve as points for
stress concentration.23 Although SMART and SelfX stents
are electropolished, the Luminexx stents we have used are
not. Luminexx has now been replaced by an electropol-
ished Luminexx in Europe. Polishment issues may affect
fracture rate of stents in the femoropopliteal artery, al-
though no significant difference in fracture rates was seen
between Luminexx and SMART in the present study.
Scheinert et al demonstrated that stent fracture in the
femoropopliteal artery is associated with a higher in-stent
restenosis rate.4 Conversely, our results do not indicate that
stent fracture following iliac artery stenting is associated
with loss of patency. Thus, stent fracture following iliac
artery stenting did not have as much impact as in femoro-
popliteal stenting. However, dilatation or ulceration of the
iliac artery was detected with severely fractured stents (types
IV and V). These results could indicate that patency is
largely a non-issue for fractured stents of the iliac artery, but
severely fractured stents appear to be associated with aneu-
rysmal dilatation and ulceration.
The present study displayed a few limitations. First,
plain radiography equipment changed during the course of
this study. The original system used computed radiography
and x-ray films. Flat-panel radiography using a viewer has
recently been used for examination of stent integrity. Some
differences in the ability to detect stent fracture may thus
exist between the initial and current systems. Second, the
pelvis is highly opaque to x-rays, particularly on lateral
projections. The ability of pelvic radiography to detect
minor fractures (types I or II) may thus be limited. Third,
this was a retrospective study, dependant upon physicians
and patient situations as to whether radiographic examina-
tion was performed, although a standard protocol of
follow-up studies was in place. Over 40% of all patients
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fracture at 12-month follow-up (a, b). The stent placed in the iliac artery bends during hip joint bending. Stent fracture
is apparent at the bend site of the stent (c). However, CT angiography shows no evidence of restenosis (d, e).
dilatation of iliac artery at the fracture site.
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this analysis due to short duration of follow-up, loss to
follow-up, or lack of adequate imaging. Additionally, the
actual mean follow-up was 43 months despite the long
study period. As time passed, the number of patients
treated using self-expanding stents increased. Furthermore,
some patients were lost to follow-up. This might weaken
the impact of this study. A prospective study would help to
clarify the issues associated with stent fracture following
iliac artery stenting.
CONCLUSION
In conclusion, fracture of a self-expanding stent is rare
in the iliac artery, while no fractures were seen involving the
Elgiloy stents. Stenting for chronic occlusion is a risk factor
for fracture. Fracture of stents placed in the iliac artery
rarely affects patency.
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